XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

Condensed Consolidated Financial Statement Detail (Tables)

9 Months Ended

Sep. 30, 2012

Condensed Consolidated Financial Statement Detail [Abstract]

Outstanding securities considered anti-dilutive

Potentially dilutive securities are excluded from the calculation of loss per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Common stock options and restricted stock units		5,730		4,036		5,788		3,837
Convertible preferred stock		-		-		-		90
Warrants for common stock		16,626		1,608		12,942		1,608
Total		22,356		5,644		18,730		5,535

Accrued liabilities

Accrued liabilities consisted of the following at September 30, 2012 and December 31, 2011 (in thousands):

	September 30, 2012		December 31, 2011
Accrued management incentive compensation	$	2,821	$	4,096
Accrued payroll and other benefits		2,510		3,007
Accrued clinical trial costs		3,940		140
Accrued severance payments		642		1,207
Other		1,754		1,562
Total	$	11,667	$	10,012